News and Announcements
Jumbo (ASX: JIN) Receives $15.6m Investment from Tatts Group, Reaches $142m TTV & Share Price Up 67%
- Published July 17, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Jumbo is a leading digital retailer of official government and charitable lotteries. Jumbo operates the world’s best digital lotto experiences by developing engaging and entertaining purchase experiences across a range of digital platforms.
The 2017 FY saw the strengthening of Jumbo’s alliance with the largest and most dominant company in the Australian Gaming Industry, with the Tatts Group investing $15.6M, and acquiring a 15% stake.
Performance
Comparing like-for-like jackpots, sales are growing consistently, with the TTV for FY2017 reaching $142M.
Jumbo’s share price has increased 67% in the past 12 months, from $1.68 this time in 2016, to $2.82 as at the time of writing.
Growth Potential
Online lottery sales are only just beginning to gain traction in Australia. Only 13% of Australian lotto tickets are sold on the Internet, whilst other countries sell over 30% of lotto tickets online, offering considerable growth potential through natural progression.
Industry development with the Tatts + Tabcorp $11B merger offers potential for further growth, with potential access to even more products.
The inclusion and expansion of Charity Lottery product offering provides high growth potential, being complimentary to National games, with minimal customer acquisition expenses.
Maximising the OzLotteries App and Website
FY2018 will see Jumbo focus on better performance and maximizing the OzLotteries App and Website assets through improved marketing campaigns using data analytics for more active customers, taking its social media campaign to the next level, and highlighting Charity lotteries to encourage increased sales.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
